endocrinology
Type 2 Diabetes Management
Step-up pharmacotherapy for T2DM — NICE NG28 individualised approach with HbA1c targets
Source: NICE NG28 2022
Step 1 of ~9
info
T2DM Management
Individualise HbA1c target. Standard target: 48 mmol/mol (6.5%) at diagnosis, 53 mmol/mol (7%) on monotherapy, 58 mmol/mol (7.5%) if risk of hypoglycaemia.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Dutasteride · 5-alpha reductase inhibitor (Type I and II)
- Neostigmine · Anticholinesterase (Reversal Agent)
- Prilocaine · Local Anaesthetic (Amide)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
- Pituitary Apoplexy · ENEA 2011 / Pituitary Society
- Hypercalcaemia Management · NICE / Endocrine Society
- Hyperosmolar Hyperglycaemic State (HHS) · NICE; JBDS; RCP — NG18
Decision support only. Always apply local guidelines and clinical judgement.